Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD123-Targeted CD16 Antibody-Modified NK Cell Immunotherapy for Refractory/Relapsed Acute Myeloid Leukemia (R/R AML)

NCT06835140 is registered in ClinicalTrials.gov with Chunji Gao as lead sponsor.

NCT NCT06835140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06835140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD123-Targeted CD16 Antibody-Modified NK Cell Immunotherapy for Refractory/Relapsed Acute Myeloid Leukemia (R/R AML)
Lead sponsor
Chunji Gao
Phase
Phase 1
Overall status
Recruiting
Start date
February 21, 2025
Completion date
December 31, 2025
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml (acute myelogenous leukemia), cd123+ acute myeloid leukemia, nk cell